A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
- Mayo Clinic, United States
- University of Wisconsin-Madison, United States
- University of California, Davis, United States
- University of California, Irvine, United States
- University of Maryland, Baltimore, United States
- The University of Texas Health Science Center at Houston, United States
- Qingdao University, China
- Shanghai Jiao Tong University, China
Abstract
Previously we showed the generation of a protein trap library made with the gene-break transposon (GBT) in zebrafish (Danio rerio) that could be used to facilitate novel functional genome annotation towards understanding molecular underpinnings of human diseases (Ichino et al, 2020). Here, we report a significant application of this library for discovering essential genes for heart rhythm disorders such as sick sinus syndrome (SSS). SSS is a group of heart rhythm disorders caused by malfunction of the sinus node, the heart's primary pacemaker. Partially owing to its aging-associated phenotypic manifestation and low expressivity, molecular mechanisms of SSS remain difficult to decipher. From 609 GBT lines screened, we generated a collection of 35 zebrafish insertional cardiac (ZIC) mutants in which each mutant traps a gene with cardiac expression. We further employed electrocardiographic measurements to screen these 35 ZIC lines and identified three GBT mutants with SSS-like phenotypes. More detailed functional studies on one of the arrhythmogenic mutants, GBT411, in both zebrafish and mouse models unveiled Dnajb6 as a novel SSS causative gene with a unique expression pattern within the subpopulation of sinus node pacemaker cardiomyocytes that partially overlaps with the expression of hyperpolarization activated cyclic nucleotide gated channel 4 (Hcn4), supporting heterogeneity of the cardiac pacemaker cells.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 4 and Figure 7.
Article and author information
Author details
Funding
Mayo Foundation for Medical Education and Research
- Xiaolei Xu
Wisconsin Partnership Program 4140
- Alexey V Glukhov
American Heart Association (17POST33370089)
- Di Lang
American Heart Association (846898)
- Di Lang
National Institute of Health (R00HL138160)
- Stefano Morotti
National Institute of Health (1OT2OD026580-01)
- Eleonora Grandi
Science and Technology Innovation Action Plan of Shanghai (201409005600)
- Yigang Li
National Institute of Health (GM063904)
- Stephen C Ekker
American Heart Association (16SDG29120011)
- Alexey V Glukhov
National Institute of Health (R00HL138160)
- Stefano Morotti
National Institute of Health (R01HL131517,P01HL141084)
- Eleonora Grandi
American Heart Association (15SDG24910015)
- Eleonora Grandi
American Heart Association (20POST35120462)
- Haibo Ni
National Institute of Health (NIH R01HL141214)
- Alexey V Glukhov
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 1996). All animal procedures and protocols used in these studies (for zebrafish, #: A00005409-20; for mouse, #: A00003511-20 and M005490-R02) have been approved by the Mayo Clinic Institutional Animal Care and Use Committee (Permit number: D16-00187) and by the Animal Care and Use Committee of University of Wisconsin-Madison (Permit number: D16-00239).
Copyright
© 2022, Ding et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,027
- views
-
- 197
- downloads
-
- 9
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
eLife 11:e77327.
https://doi.org/10.7554/eLife.77327
Further reading
-
- Developmental Biology
- Genetics and Genomics
The establishment and growth of the arterial endothelium requires the coordinated expression of numerous genes. However, regulation of this process is not yet fully understood. Here, we combined in silico analysis with transgenic mice and zebrafish models to characterize arterial-specific enhancers associated with eight key arterial identity genes (Acvrl1/Alk1, Cxcr4, Cxcl12, Efnb2, Gja4/Cx37, Gja5/Cx40, Nrp1 and Unc5b). Next, to elucidate the regulatory pathways upstream of arterial gene transcription, we investigated the transcription factors binding each arterial enhancer compared to a similar assessment of non-arterial endothelial enhancers. These results found that binding of SOXF and ETS factors was a common occurrence at both arterial and pan-endothelial enhancers, suggesting neither are sufficient to direct arterial specificity. Conversely, FOX motifs independent of ETS motifs were over-represented at arterial enhancers. Further, MEF2 and RBPJ binding was enriched but not ubiquitous at arterial enhancers, potentially linked to specific patterns of behaviour within the arterial endothelium. Lastly, there was no shared or arterial-specific signature for WNT-associated TCF/LEF, TGFβ/BMP-associated SMAD1/5 and SMAD2/3, shear stress-associated KLF4 or venous-enriched NR2F2. This cohort of well characterized and in vivo-verified enhancers can now provide a platform for future studies into the interaction of different transcriptional and signalling pathways with arterial gene expression.
-
- Genetics and Genomics
Heritable fragile bone disorders (FBDs), ranging from multifactorial to rare monogenic conditions, are characterized by an elevated fracture risk. Validating causative genes and understanding their mechanisms remain challenging. We assessed a semi-high throughput zebrafish screening platform for rapid in vivo functional testing of candidate FBD genes. Six genes linked to severe recessive osteogenesis imperfecta (OI) and four associated with bone mineral density (BMD) from genome-wide association studies were analyzed using CRISPR/Cas9-based crispant screening in F0 mosaic founder zebrafish. Next-generation sequencing confirmed high indel efficiency (mean 88%), mimicking stable knock-out models. Skeletal phenotyping at 7, 14, and 90 days post-fertilization (dpf) using microscopy, Alizarin Red S staining, and microCT was performed. Larval crispants showed variable osteoblast and mineralization phenotypes, while adult crispants displayed consistent skeletal defects, including malformed neural and haemal arches, vertebral fractures and fusions, and altered bone volume and density. In addition, aldh7a1 and mbtps2 crispants experienced increased mortality due to severe skeletal deformities. RT-qPCR revealed differential expression of osteogenic markers bglap and col1a1a, highlighting their biomarker potential. Our results establish zebrafish crispant screening as a robust tool for FBD gene validation, combining skeletal and molecular analyses across developmental stages to uncover novel insights into gene functions in bone biology.
